Antibodies

28 Jun 2018 BioAtla Announces First Patient Treated In Phase1/2 BA3021-001 Clinical Trial For CAB-ROR2-ADC Therapeutic
28 Jun 2018 Arsanis Provides Update Following Completion of Planned Interim Analysis of Phase 2 Clinical Trial of ASN100
28 Jun 2018 Kymab Announces Agreement to Evaluate KY1044, its Novel Antibody Targeting ICOS, and Anti-PD-L1 Immunotherapy for testing in Multiple Solid Tumors
28 Jun 2018 Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)
28 Jun 2018 argenx receives second preclinical milestone payment under its development agreement with AbbVie
27 Jun 2018 Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
27 Jun 2018 aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
26 Jun 2018 FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma
25 Jun 2018 Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
25 Jun 2018 Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
25 Jun 2018 Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy
22 Jun 2018 U.S. Food and Drug Administration (FDA) Accepts Application for Opdivo Plus Low-Dose Yervoy for Treatment of First-Line Non-Small Cell Lung Cancer in Patients with Tumor Mutational Burden ≥10 mut/Mb
21 Jun 2018 Alligator Bioscience's ATOR-1017 Strongly Activates Both T cells and NK Cells, Important for the Effective Eradication of Tumor Cells
20 Jun 2018 Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
19 Jun 2018 Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO® (blinatumomab) Label
19 Jun 2018 Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.
19 Jun 2018 How many PD-1 and PD-L1 checkpoint inhibitors do we need?
19 Jun 2018 Celltrion Completes Resubmission to FDA for Proposed Trastuzumab Biosimilar
18 Jun 2018 Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma
16 Jun 2018 Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache
15 Jun 2018 Amphivena Demonstrates at EHA First Human Proof-of-Concept For AMV564 in Relapsed/Refractory AML
15 Jun 2018 Sandoz presents new long-term and switching data for biosimilars Zessly® (infliximab) and Erelzi® (etanercept) in rheumatoid arthritis
15 Jun 2018 Affimed Announces Updated Data of AFM13 in Combination with Keytruda® (Pembrolizumab) in Patients with Relapsed/Refractory Hodgkin Lymphoma Presented at EHA
14 Jun 2018 Trillium Therapeutics Doses First Patient With TTI-622, Its Second Immune Checkpoint Inhibitor Targeting CD47
14 Jun 2018 Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up
Top